Xencor (XNCR) Competitors $23.07 -0.43 (-1.83%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends XNCR vs. KURA, ZYME, AIMT, MGNX, PRLD, CYTK, VKTX, BPMC, NUVL, and LNTHShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Kura Oncology (KURA), Zymeworks (ZYME), Aimmune Therapeutics (AIMT), MacroGenics (MGNX), Prelude Therapeutics (PRLD), Cytokinetics (CYTK), Viking Therapeutics (VKTX), Blueprint Medicines (BPMC), Nuvalent (NUVL), and Lantheus (LNTH). These companies are all part of the "medical" sector. Xencor vs. Kura Oncology Zymeworks Aimmune Therapeutics MacroGenics Prelude Therapeutics Cytokinetics Viking Therapeutics Blueprint Medicines Nuvalent Lantheus Kura Oncology (NASDAQ:KURA) and Xencor (NASDAQ:XNCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, community ranking, valuation, earnings and institutional ownership. Which has more risk & volatility, KURA or XNCR? Kura Oncology has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Is KURA or XNCR more profitable? Kura Oncology has a net margin of 0.00% compared to Xencor's net margin of -232.77%. Xencor's return on equity of -30.92% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Kura OncologyN/A -44.09% -39.57% Xencor -232.77%-30.92%-21.74% Does the media favor KURA or XNCR? In the previous week, Xencor had 2 more articles in the media than Kura Oncology. MarketBeat recorded 16 mentions for Xencor and 14 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.77 beat Xencor's score of 0.62 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 5 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in KURA or XNCR? Xencor received 86 more outperform votes than Kura Oncology when rated by MarketBeat users. Likewise, 73.36% of users gave Xencor an outperform vote while only 69.32% of users gave Kura Oncology an outperform vote. CompanyUnderperformOutperformKura OncologyOutperform Votes41869.32% Underperform Votes18530.68% XencorOutperform Votes50473.36% Underperform Votes18326.64% Do analysts recommend KURA or XNCR? Kura Oncology currently has a consensus target price of $28.83, indicating a potential upside of 81.11%. Xencor has a consensus target price of $35.75, indicating a potential upside of 54.96%. Given Kura Oncology's higher probable upside, equities analysts plainly believe Kura Oncology is more favorable than Xencor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kura Oncology 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Xencor 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, KURA or XNCR? Xencor has higher revenue and earnings than Kura Oncology. Xencor is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKura OncologyN/AN/A-$152.63M-$2.36-6.75Xencor$168.34M9.59-$126.09M-$3.20-7.21 SummaryXencor beats Kura Oncology on 7 of the 13 factors compared between the two stocks. Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.61B$6.53B$5.15B$8.74BDividend YieldN/A8.16%5.18%4.08%P/E Ratio-7.214.7865.5913.48Price / Sales9.59377.381,278.7587.67Price / CashN/A51.2039.7035.24Price / Book2.249.686.475.93Net Income-$126.09M$154.43M$119.73M$225.73M7 Day Performance-2.33%-9.46%-5.13%-1.34%1 Month Performance8.01%-7.27%-2.71%1.15%1 Year Performance20.03%28.13%31.08%24.02% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor3.604 of 5 stars$23.07-1.8%$35.75+55.0%+24.4%$1.61B$168.34M-7.21280Insider SellingHigh Trading VolumeKURAKura Oncology4.1158 of 5 stars$15.81-4.1%N/A+75.1%$1.23BN/A-6.70142Analyst UpgradeShort Interest ↑ZYMEZymeworks2.1027 of 5 stars$15.36-5.5%N/A+97.8%$1.06B$76.01M-10.24290AIMTAimmune TherapeuticsN/A$34.49flatN/AN/A$2.26BN/A-7.68228News CoverageMGNXMacroGenics3.8281 of 5 stars$3.60-5.5%N/A-49.6%$225.94M$58.75M-2.28430PRLDPrelude Therapeutics2.7966 of 5 stars$1.03flatN/A-69.4%$56.69M$3M-0.58120Short Interest ↑CYTKCytokinetics4.0709 of 5 stars$51.25-6.3%N/A+58.5%$6.05B$3.22M-9.53250Insider SellingVKTXViking Therapeutics4.5139 of 5 stars$51.90-3.1%N/A+370.8%$5.78BN/A-55.8120BPMCBlueprint Medicines3.0865 of 5 stars$90.90-5.0%N/A+41.6%$5.77B$249.38M-43.08640Analyst ForecastShort Interest ↑News CoverageNUVLNuvalent3.1126 of 5 stars$88.78-1.6%N/A+49.7%$5.75BN/A-25.5940Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLNTHLantheus4.6106 of 5 stars$78.69-2.7%N/A+12.7%$5.47B$1.30B13.09834Gap Down Related Companies and Tools Related Companies Kura Oncology Alternatives Zymeworks Alternatives Aimmune Therapeutics Alternatives MacroGenics Alternatives Prelude Therapeutics Alternatives Cytokinetics Alternatives Viking Therapeutics Alternatives Blueprint Medicines Alternatives Nuvalent Alternatives Lantheus Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XNCR) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XNCR Stock Alerts